Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate
NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today presented results from a pre-clinica...
SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific
knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...
Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions
- Late-Breaking Abstract Accepted -
SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) tr...
Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
Risk of death at five years is lower for aneurysm patients treated with coil embolization compared to surgical clipping
NATICK, Mass., May 26 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today welcomed publication of results from the ISAT clinical trial in The Lancet...
Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
NATICK, Mass., May 20 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disea...
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
TAXUS(R) Element(TM) Stent now available in select markets worldwide
NATICK, Mass., May 19 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced the launch of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets...
Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced data from its ALTITUDE Clinical Science program that show real-word survival rates for implantable cardiac device patients exceeding rates from clinical trials. ALTITUDE analyzes outcomes ...
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
Data from landmark trial provide important insight for physicians in treating heart attack patients
NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today welcomed the publication of results from the HORIZONS AMI trial in this week's issue of the New...
Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC...
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Journal of American College of Cardiology publishes positive ATLAS clinical data
NATICK, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final modules of the Company's...
Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
PLATINUM clinical program to evaluate PROMUS(TM) Element(TM) Platinum Chromium Stent
NATICK, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced the beginning of patient enrollment in the PLATINUM clinical trial, which is designed to evaluate t...
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Phase 1 Data Demonstrate Safety and Improvement in Heart Failure in a Majority of Patients
NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced
today results from the first nine patients treated with MYDICAR(R), a
genetically-targeted enzyme replacement ...
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola
Pharmaceuticals, a biopharmaceutical company developing innovative drugs
that provide significant advances in cardiovascular and inflammatory
diseases, and cancer, today announced that data relevant to betrixaban, the
company's novel ...
Cytopia Scientific Presentations on JAK2 Inhibitor Program
MELBOURNE, Australia, Oct. 16 /PRNewswire/ -- Cytopia Limited (ASX:
CYT) will present data on its JAK2 inhibitor program at two important
scientific meetings this month.
Dr Emmanuelle Fantino, Head of Biology at Cytopia, will present a
lecture entitled Targeted JAK2 Inhibitors for Myeloproli...
Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
NATICK, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced the schedule of the Company's major
events and press announcements at the Cardiovascular Research Foundation's
(CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT)
Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
PERSEUS clinical program to evaluate TAXUS(R) Element(TM) Platinum Chromium Stent
NATICK, Mass., Oct. 8 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced that it has completed enrollment in
the PERSEUS trial, designed to evaluat...
Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
SAN DIEGO, Oct. 7 /PRNewswire/ -- Prometheus Laboratories Inc., a
specialty pharmaceutical company, today announced findings from its
development of PROMETHEUS(R) IBS Diagnostic, the first and only blood test
for irritable bowel syndrome (IBS). The findings suggest measurable
differences in th...
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Study Showed Larazotide Acetate Prevented Immunologic Changes Induced by Gluten in Patients with Celiac Disease
Additional Data Indicates Potential in Treating Inflammatory Bowel Disease
ORLANDO, Fla., Oct. 7 /PRNewswire/ -- Alba Therapeutics Corporation
presented results from...
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Data support the therapeutic potential of Amylin's integrated neurohormonal approach to obesity pharmacotherapy
SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN ) today announced that new data for its pipeline obesity
candidates will be pre...
American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression
Studies show that depression is about three times more common in
patients following a heart attack than in the general community.
Heart patients should be screened for depression, and treated if
DALLAS, Sept. 30 /PRNewswire-USNewswire/ -- Heart patients should be
screened for de...
Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
SAN MATEO, Calif., Sept. 24 /PRNewswire/ -- Anthera Pharmaceuticals
announced today they have reached agreement with the U.S. Food and Drug
Administration (FDA) on a Phase 3 protocol for varespladib (A-002) in acute
coronary syndrome (ACS) under the FDA's Special Protocol Assessment
Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
- Comprehensive Phase 3 Clinical Program Initiated -
CAMBRIDGE, Mass. and NEW YORK, Sept. 23 /PRNewswire-FirstCall/ --
Ironwood Pharmaceuticals (formerly Microbia) and Forest Laboratories, Inc.
(NYSE: FRX ) today announced they will present results of a Phase 2b study
Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin
Technologies, Inc. (Amex: PTN ) announced it presented results from a Phase
1 clinical study with PL-3994, a novel, long-acting natriuretic peptide
receptor A (NPRA) agonist under development for treatment of the chronic
treatment of ...
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released Concurrent with AHA Presentation
SAN FRANCISCO, Sept. 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals,
Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of
compounds for the treat...
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA ) today announced that preclinical data will be presented on
the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,
at the American College of Gastroenterology Annual Scientific
Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
Company to present data from landmark SYNTAX clinical trial
NATICK, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced the schedule of the Company's major
events and press announcements at the European Society of Cardiology
Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community
Study findings offer hope for increased life expectancy for people with
WASHINGTON, Aug. 18 /PRNewswire-USNewswire/ -- In the world of Down
syndrome, 'Mr. C' is a rarity. A real person whose progress has been
tracked for the past 16 years, at seventy, 'Mr. C' has well surpassed...
Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.
("Rib-X" or the "Company"), a development-stage company focused on the
discovery and development of novel antibiotics for the treatment of
antibiotic-resistant infections, announced today that company
representatives are givi...
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Company's End-of-Phase II Meeting with FDA Set for Sept. 29
LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics,
Inc. (Nasdaq: TPTX ) today announced that data presented at the 50th Annual
Scientific Meeting of the American Headache Society showed that, in
addition to mee...
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will present
results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for
the treatment of migraine headache at the 50th Annual Scientific
Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
SOUTH EASTON, Mass., May 21 /PRNewswire-FirstCall/ -- Pressure
BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today announced that scientists
from the New York University (NYU) School of Medicine, the Brooklyn
Hospital Center, and the Harvard School of Public Health made presentations
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ --
Corporation (NYSE: BSX ) today welcomed two-year results
from the SPIRIT III clinical trial, which continue to reaffirm the proven
long-term safety and efficacy of the market-leading TAXUS(R) Express2(TM)
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
VYVANSE demonstrated significant improvement in ADHD symptoms in adults
WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, today
presented the results of a phase III pivotal study in which VYVANSE
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ),
a global specialty pharmaceutical company, today announced results from
clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate
extended-release with sequestered naltrexone hydrochloride) capsules
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
PHILADELPHIA, May 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced
today that it will present key scientific
data on its Attention Deficit
Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate,
Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
HONG KONG, May 1 /PRNewswire/ -- The clinical impact of the first-ever
pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, is the
subject of a symposium at next month's 16th Annual Scientific
the Hong Kong College of Cardiology.
Scheduled for May 3 at the Sheraton Hong...
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics
(Nasdaq: NKTR ) announced today that positive preclinical and clinical
results for its pipeline programs will be presented at numerous medical and
scientific meetings over the coming months. These presentations will
Arpida Invited to Present Data on Iclaprim at Scientific Conference
REINACH, Switzerland, April 9 /PRNewswire-FirstCall/ -- Arpida Ltd.
(SWX: ARPN) announced today that a total of 13 abstracts on iclaprim have
been accepted for the upcoming 18th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID) which takes place in
Barcelona, 19-22 Ap...
Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
WALTHAM, Mass., April 3, 2008 /PRNewswire-FirstCall/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO ), the world leader in serving science, announced
that it has received U.S. Food and Drug Administration (FDA) clearance for
Spectra(TM) MRSA, a test designed to screen for methicillin-resistant